Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 30, 2026
UBS (UBS) Reports Strong Q2 2026 Results with +17% Profit Growth

UBS (UBS) Reports Strong Q2 2026 Results with +17% Profit Growth

Key Takeaways

  • Net profit reached $2.8 billion in the second quarter, comfortably exceeding the analyst consensus estimate of $2.39 billion and rising 17% year over year.
  • Global Wealth Management attracted $36 billion in net new assets, significantly outpacing analyst forecasts of roughly $21 billion, underscoring strong client confidence in the combined UBS–Credit Suisse franchise.
  • The Investment Bank posted a record second-quarter performance, with pre-tax profit more than doubling to $1.2 billion, driven by surging equities trading and capital markets activity.
  • A new $3 billion share buyback program was announced, with at least $1 billion expected to be repurchased over the next three months, following the completion of the prior $3 billion program in July.
  • Cumulative cost savings from the Credit Suisse integration reached $12.6 billion, representing more than 90% of the $13.5 billion target, with the integration on track for substantial completion by year-end 2026.
  • The internal workforce fell below 100,000 for the first time since the Credit Suisse acquisition, reflecting disciplined headcount management as legacy IT systems are decommissioned.

Earnings Context and Why It Matters

UBS Group AG's second-quarter 2026 results mark a pivotal moment in the bank's post-acquisition journey. Nearly three years after the government-brokered rescue of Credit Suisse, this earnings release provides the clearest evidence yet that the merger thesis is delivering on its promises. With integration milestones accelerating, cost savings materializing ahead of schedule, and client flows remaining robust, the quarter offered investors a tangible progress report on one of the most complex banking integrations in modern history. The results also arrive at a critical juncture for Swiss banking regulation, as Parliament deliberates on capital requirements that could materially shape UBS's future capital return capacity. For the market, this earnings report serves as a dual test: sustaining organic business momentum while navigating unresolved regulatory headwinds.

The Reported Numbers

UBS reported net profit attributable to shareholders of $2.8 billion for the second quarter of 2026, exceeding the company-provided analyst consensus of $2.39 billion. Earnings per share (EPS) came in at $0.87, while group revenue rose 16% year over year to $13.3 billion. Underlying pre-tax profit surged 45% to $3.9 billion, and the underlying return on CET1 capital reached 16.4%.

Global Wealth Management generated $2 billion in pre-tax profit, up 38% from the prior-year quarter, supported by $36 billion in net new assets. The Investment Bank delivered exceptional results with pre-tax profit of $1.2 billion — more than double the year-ago figure — on revenue of $3.7 billion, a 31% increase. Asset Management posted pre-tax profit of $237 million, up 9%, with assets under management surpassing $2.2 trillion. The Personal and Corporate Banking division contributed CHF 676 million in pre-tax profit, a 21% increase, while group credit loss expenses remained contained at CHF 61 million.

The bank's CET1 capital ratio stood at 14.4% at quarter-end, and the group's cost-to-income ratio improved to 70% on an underlying basis. Cumulative gross cost savings from the Credit Suisse integration reached $12.6 billion, placing UBS well within reach of its $13.5 billion target. Total invested assets across the group climbed to a record $7.3 trillion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

UBS shares rose approximately 1% to 3% in early trading following the results, with the stock trading near the upper end of its 52-week range. The positive but measured market reaction reflected a balance between strong underlying performance and lingering cautiousness around the pace of future capital returns. While net profit comfortably beat consensus, headline EPS of $0.87 fell slightly short of some third-party estimates, and revenue was broadly in line with or marginally below certain forecasts. Analysts at Vontobel noted that the earnings beat was concentrated in investment banking trading, with the other three operating divisions exceeding consensus by a narrower margin. Nonetheless, the $36 billion wealth management inflow — nearly double some analyst forecasts — and the new $3 billion buyback commitment were widely viewed as signals of confidence from management. Sentiment heading into the quarter had been cautiously optimistic, and the results largely validated that positioning, though unresolved Swiss capital regulation remains a key overhang for longer-term institutional investors.

Forward Outlook and Key Factors to Monitor

Looking ahead, UBS enters the second half of 2026 with several tailwinds and a few unresolved challenges. The most immediate catalyst for investors is the progress of Swiss parliamentary deliberations on capital requirements for systemically important banks, with the next key committee session scheduled for mid-August. The proposed framework could require UBS to hold an additional $20 billion or more in CET1 capital against its foreign subsidiaries — a requirement CEO Sergio Ermotti has publicly described as excessive and competitively damaging. Any softening of that stance by lawmakers would likely be received positively by the market and could unlock a faster pace of share buybacks beyond the newly announced $3 billion program.

On the operational side, the Credit Suisse integration is approaching its final chapter. With over 90% of legacy IT applications no longer in use and roughly 70% already fully decommissioned, UBS is targeting substantial completion by the end of 2026. Achieving this milestone would remove one of the largest execution risks that has hung over the stock since the 2023 acquisition.

Investors should also monitor wealth management flows in the Americas, where elevated advisor attrition has created pockets of client outflow. The division posted $1 billion in net inflows during Q2 even after a $10 billion seasonal tax-related outflow, offering early signs of stabilization. Meanwhile, management cautioned that geopolitical uncertainty, volatile energy prices, and potential shifts in inflation and interest rate expectations could create temporary headwinds in the third quarter, even as underlying client activity remains healthy and supportive of continued revenue growth. I reviewed recent patterns with Tickeron’s AI Real Time Patterns to gauge potential near-term moves.

Using Tickeron’s AI Screener in My Research

When evaluating financial names like this one, I often turn to Tickeron’s AI Screener to filter peers by metrics such as revenue growth, capital ratios, and AI signals. It helps me quickly spot how UBS stacks up against the broader sector without spending hours on manual screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UBS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for UBS turns positive, indicating new upward trend

UBS saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UBS advanced for three days, in of 347 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 322 cases where UBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for UBS moved out of overbought territory on July 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for UBS turned negative on July 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

UBS broke above its upper Bollinger Band on July 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 19, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.983) is normal, around the industry mean (1.953). UBS's P/E Ratio (34.079) is considerably higher than the industry average of (16.333). Projected Growth (PEG Ratio) (0.892) is also within normal values, averaging (1.625). Dividend Yield (0.020) settles around the average of (0.025) among similar stocks. UBS's P/S Ratio (8.547) is very high in comparison to the industry average of (4.356).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 217.83B. The market cap for tickers in the group ranges from 1.04M to 970.72B. JPM holds the highest valuation in this group at 970.72B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was 1%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 24%. NTB experienced the highest price growth at 3%, while FRBT experienced the biggest fall at -1%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was -39%. For the same stocks of the Industry, the average monthly volume growth was -13% and the average quarterly volume growth was -63%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 30
Price Growth Rating: 41
SMR Rating: 8
Profit Risk Rating: 19
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
UBS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Profile
Details
Industry
Major Banks
Address
Bahnhofstrasse 45
Phone
+41 442341111
Employees
112842
Web
https://www.ubs.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.